Amedisys Statistics
Total Valuation
Amedisys has a market cap or net worth of $3.04 billion. The enterprise value is $3.20 billion.
| Market Cap | 3.04B |
| Enterprise Value | 3.20B |
Important Dates
The next estimated earnings date is Wednesday, April 23, 2025, after market close.
| Earnings Date | Apr 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Amedisys has 32.81 million shares outstanding. The number of shares has increased by 1.39% in one year.
| Current Share Class | 32.81M |
| Shares Outstanding | 32.81M |
| Shares Change (YoY) | +1.39% |
| Shares Change (QoQ) | -1.16% |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 90.37% |
| Float | 32.04M |
Valuation Ratios
The trailing PE ratio is 70.76 and the forward PE ratio is 19.46. Amedisys's PEG ratio is 1.30.
| PE Ratio | 70.76 |
| Forward PE | 19.46 |
| PS Ratio | 1.29 |
| Forward PS | 1.21 |
| PB Ratio | 2.68 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.13 |
| P/OCF Ratio | 13.72 |
| PEG Ratio | 1.30 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.57, with an EV/FCF ratio of 14.86.
| EV / Earnings | 73.94 |
| EV / Sales | 1.36 |
| EV / EBITDA | 13.57 |
| EV / EBIT | 15.25 |
| EV / FCF | 14.86 |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.39.
| Current Ratio | 1.23 |
| Quick Ratio | 1.18 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 1.67 |
| Debt / FCF | 2.14 |
| Interest Coverage | 6.81 |
Financial Efficiency
Return on equity (ROE) is 3.32% and return on invested capital (ROIC) is 8.07%.
| Return on Equity (ROE) | 3.32% |
| Return on Assets (ROA) | 6.24% |
| Return on Invested Capital (ROIC) | 8.07% |
| Return on Capital Employed (ROCE) | 12.90% |
| Revenue Per Employee | $123,596 |
| Profits Per Employee | $2,275 |
| Employee Count | 19,000 |
| Asset Turnover | 1.12 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Amedisys has paid $48.05 million in taxes.
| Income Tax | 48.05M |
| Effective Tax Rate | 55.74% |
Stock Price Statistics
The stock price has increased by +0.55% in the last 52 weeks. The beta is 0.76, so Amedisys's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +0.55% |
| 50-Day Moving Average | 92.28 |
| 200-Day Moving Average | 93.78 |
| Relative Strength Index (RSI) | 54.92 |
| Average Volume (20 Days) | 304,370 |
Short Selling Information
The latest short interest is 2.66 million, so 8.10% of the outstanding shares have been sold short.
| Short Interest | 2.66M |
| Short Previous Month | 2.89M |
| Short % of Shares Out | 8.10% |
| Short % of Float | 8.30% |
| Short Ratio (days to cover) | 7.16 |
Income Statement
In the last 12 months, Amedisys had revenue of $2.35 billion and earned $43.23 million in profits. Earnings per share was $1.31.
| Revenue | 2.35B |
| Gross Profit | 1.02B |
| Operating Income | 209.57M |
| Pretax Income | 143.78M |
| Net Income | 43.23M |
| EBITDA | 235.61M |
| EBIT | 209.57M |
| Earnings Per Share (EPS) | $1.31 |
Balance Sheet
The company has $303.24 million in cash and $459.30 million in debt, giving a net cash position of -$156.06 million or -$4.76 per share.
| Cash & Cash Equivalents | 303.24M |
| Total Debt | 459.30M |
| Net Cash | -156.06M |
| Net Cash Per Share | -$4.76 |
| Equity (Book Value) | 1.18B |
| Book Value Per Share | 34.61 |
| Working Capital | 117.69M |
Cash Flow
In the last 12 months, operating cash flow was $221.67 million and capital expenditures -$6.55 million, giving a free cash flow of $215.12 million.
| Operating Cash Flow | 221.67M |
| Capital Expenditures | -6.55M |
| Free Cash Flow | 215.12M |
| FCF Per Share | $6.56 |
Margins
Gross margin is 43.34%, with operating and profit margins of 8.92% and 1.84%.
| Gross Margin | 43.34% |
| Operating Margin | 8.92% |
| Pretax Margin | 3.67% |
| Profit Margin | 1.84% |
| EBITDA Margin | 10.03% |
| EBIT Margin | 8.92% |
| FCF Margin | 9.16% |
Dividends & Yields
Amedisys does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.39% |
| Shareholder Yield | -1.39% |
| Earnings Yield | 1.42% |
| FCF Yield | 7.08% |
Analyst Forecast
The average price target for Amedisys is $100.80, which is 8.82% higher than the current price. The consensus rating is "Hold".
| Price Target | $100.80 |
| Price Target Difference | 8.82% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 5, 2006. It was a forward split with a ratio of 1.33333:1.
| Last Split Date | Dec 5, 2006 |
| Split Type | Forward |
| Split Ratio | 1.33333:1 |
Scores
Amedisys has an Altman Z-Score of 3.93 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.93 |
| Piotroski F-Score | 7 |